Stephen Gitelman, MD

Title(s)Professor, Pediatrics
SchoolSchool of Medicine
Address550 16th Street, #4804
San Francisco CA 94158
Phone415-476-3748
PronounsHe/Him/His
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPost-Doc Fellow/Scholar1990Pediatric Endocrinology
    University of California, San Francisco ResidencyPediatrics
    University of North CarolinaM.D.1984School of Medicine

    Collapse Overview 
    Collapse Overview
    Dr. Gitelman is a physician scientist involved in studies to determine what causes type 1 diabetes mellitus (T1DM), and in clinical trials to prevent disease development, or preserve beta cell function in those recently diagnosed. To this end, he has been an active investigator in the NIH-sponsored TrialNet and Immune Tolerance Network consortia, and other immunotherapy trials in T1DM. He also has broad research interests in defining subtypes of T1D, optimizing clinical care of those living with diabetes, and in mentoring the next generation of physician scientists in Pediatric Endocrinology.

    Collapse Research 
    Collapse Research Activities and Funding
    TrialNet Publications Committee Chair
    University of South Florida (NIH/NIDDK) U01DK106993Apr 1, 2022 - Jun 30, 2025
    Role: TrialNet Publications Committee Chair
    Description: Dr. Gitelman will serve as Publications Committee Chair, partnering with the TrialNet Publications Office.
    ITN Study: Siplizumab T1D Study
    Benaroya Research Institute / NIH NIAID Subcontract FY20ITN372Jun 1, 2020 - Jan 31, 2026
    Role: Principal Investigator
    Description: The protocol Development Chair will have an overall responsibility for the study development and protocol creation. The Protocol Development Chair will also interact with regulatory agencies, as needed, for the matters regarding this clinical trial. The protocol Chair will work under the guidance of the Immune Tolerance Network members.
    UCSF TrialNet
    NIH U01DK106993May 1, 2020 - Jun 30, 2025
    Role: Principal Investigator
    Description: The goal of this study is to establish and maintain a Clinical Center of TrialNet at the University of California at San Francisco (UCSF), with the ultimate long-term objective to develop therapies to prevent type 1 diabetes.
    Diabetes Autoimmunity Withdrawn in New Onset and In Established Patients
    Tolerion, Inc. Private GrantNov 4, 2019 - Nov 4, 2024
    Role: Principal Investigator
    Description: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety of TOL-3021 in Patients with New Onset or Established type 1 Diabetes Mellitus.
    Rituximab Followed by Abatacept for Prevention or Reversal of Type 1 Diabetes (T1D)
    Helmsley Charitable Trust A134421Oct 1, 2019 - Sep 30, 2021
    Role: Principal Investigator
    Description: To develop safe and effective means to delay or prevent progression to T1D among those with multiple antibodies and abnormal glucose tolerance. This funding is intended to support the purchase of Rituximab, in sufficient quantity to complete the trial.
    A Multicenter, Multinational Extension of Study PRV-031-001
    Provention Bio, Inc. 136738AAug 20, 2019 - Mar 9, 2026
    Role: Principal Investigator
    Description: The goal of this study is to evaluate the long-term safety of Teplizumab (PRV-031), a humanized, FcR non-binding, anti-CD3 monoclonal antibody, in children and adolescents with recent-onset Type 1 diabetes mellitus.
    Novel metabolic evaluation of new onset type 1 diabetes trials
    Indiana University 1R32DK119800Jul 1, 2019 - Apr 30, 2024
    Role: Principal Investigator
    Description: The goal of the study is to assess beta cell glucose sensitivity in new onset trials in type 1 diabetes, including use of imatinib, as well as other trials conducted in TrialNet and the Immune Tolerance Network.
    19-27179, PROTECT
    Provention Bio, Inc PRV-031-001May 1, 2019 - Mar 9, 2026
    Role: Principal Investigator
    Description: A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Diabetes (T1D).
    A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in subjects with clinical recent-onset Type 1 Diabetes Mellitus (T1D)
    IntrexonT1D Partners, LLC Private GrantFeb 23, 2019 - Feb 23, 2025
    Description: The goal of this study is to evaluate a modified Lactococcus secreting IL-10 and pro-insulin without or with anti-CD3 monoclonal antibody in an early clinical trial in type 1 diabetes to assess safety and possible efficacy.
    SIMPONI to arrest beta cell loss in type 1 diabetes (the T1GER study)
    Janssen Research and Development Private GrantFeb 1, 2017 - Mar 16, 2025
    Role: Principal Investigator
    Description: The goal of this proposal will be to evaluate the safety and efficacy of Simponi in a phase 2 trial in new onset type 1 diabetes.
    A phase 2 trial to assess safety and efficacy of polyclonal Treg therapy in new onset Type 1 Diabetes
    Caladrius Biosciences Private GrantApr 1, 2016 - Nov 8, 2021
    Role: Principal Investigator
    Description: The goal of this multi-center study is to conduct a phase II study to assess safety and efficacy of autologous ex vivo expanded polyclonal regulatory T cells (Tregs) in new onset type 1 diabetes.
    ITN066AI (T1DES): Initial Participants Participated in T1DAL, Receiving Alefacept, and AbATE, Receiving Teplizumab
    Benaroya Research Institute / NIH NIAID Subcontract FY16ITN182Feb 1, 2016 - Jun 30, 2027
    Role: Principal Investigator
    Description: The goal of this study is to conduct long term follow up of subjects in prior clinical research studies, and assess durability of effects on beta cell function, and any possible long term safety concerns.
    Diabetes Endocrinology Research Center
    NIH/NIDDK P30DK063720Apr 1, 2015 - Mar 31, 2022
    Role: Co-Investigator, Program Director of Translation
    Description: The goal of the Center is to support a highly interactive team investigating type 1 and type 2 diabetes to advance the study and treatment of the disease. The Center encompasses a broad range of intellectual and research expertise from 21 departments and research units and 4 UCSF campuses focused on both basic and clinical research. I oversee the program in translational research.
    ITN058AI EXTEND - Preserving Beta-Cell Function with Tocilzumab in New Onset Type 1 Diabetes
    Benaroya Research Institute / NIH NIAID Subcontract FY15ITN104Sep 1, 2014 - Jan 31, 2022
    Role: Principal Investigator
    Description: The goal of this study is to determine whether tocilizumab will slow the progression of the autoimmune destruction of ß cells and lead to the preservation of C-peptide secretion in T1DM.
    Safety and efficacy of Imatinib (Gleevec) for preserving Beta-cell function in new onset type 1 diabetes
    Juvenile Diabetes Research Foundation 17-2013-6Oct 1, 2013 - Mar 31, 2020
    Role: Principal Investigator
    Description: The goal of this study will be to determine if Imatinib is a safe and effective means to preserve endogenous insulin secretion in subjects with new onset type 1diabetes. I will serve as the study PI on this phase 2 trial.
    K12 In Diabetes (KIDS)
    NIH K12DK094726Sep 16, 2011 - Jun 30, 2017
    Role: Principal Investigator
    VGR-1/BMP-6 AND CHONDROGENESIS AND OSTEOGENESIS
    NIH K08AR001897Apr 1, 1993 - Mar 31, 1998
    Role: Principal Investigator
    PEDIATRIC CLINICAL RESEARCH CENTER
    NIH M01RR001271Dec 1, 1981 - Mar 31, 2007
    Role: Co-Investigator
    Training Program in Pediatric Endocrinology
    NIH/NIDDK T32DK007161Jul 1, 1976 - Jun 30, 2027
    Role: Principal Investigator
    Description: Produce innovative scientific and clinical leaders in this field of Pediatric Endocrinology fellows, committed to academic careers by fostering scientific career development.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Time to reframe the disease staging system for type 1 diabetes. Lancet Diabetes Endocrinol. 2024 Dec; 12(12):924-933. Jacobsen LM, Atkinson MA, Sosenko JM, Gitelman SE. PMID: 39608963.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials. Diabetes Care. 2024 Jun 01; 47(6):1048-1055. Jacobsen LM, Cuthbertson D, Bundy BN, Atkinson MA, Moore W, Haller MJ, Russell WE, Gitelman SE, Herold KC, Redondo MJ, Sims EK, Wherrett DK, Moran A, Pugliese A, Gottlieb PA, Sosenko JM, Ismail HM, Type 1 Diabetes TrialNet Study Group. PMID: 38621411; PMCID: PMC11294635.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes. Sci Transl Med. 2024 05 08; 16(746):eadn2404. Bender C, Wiedeman AE, Hu A, Ylescupidez A, Sietsema WK, Herold KC, Griffin KJ, Gitelman SE, Long SA, T-Rex Study Group†, T-Rex Clinical Study Group. PMID: 38718135.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    4. The Role of Imatinib in Pediatric Type 1 Diabetes. JCEM Case Rep. 2024 May; 2(5):luae065. Lavelle K, Chamberlain C, German M, Anderson M, Nip A, Gitelman SE. PMID: 38707652; PMCID: PMC11066799.
      View in: PubMed   Mentions:
    5. Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice. Horm Res Paediatr. 2024 Apr 30; 1-12. Mehta S, Ryabets-Lienhard A, Patel N, Breidbart E, Libman I, Haller MJ, Simmons KM, Sims EK, DiMeglio LA, Gitelman SE, Griffin KJ, Tonyushkina KN. PMID: 38663372.
      View in: PubMed   Mentions: 2     Fields:    
    6. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care. 2023 11 01; 46(11):2035-2043. Libman I, Bingley PJ, Becker D, Buckner JH, DiMeglio LA, Gitelman SE, Greenbaum C, Haller MJ, Ismail HM, Krischer J, Moore WV, Moran A, Muir AB, Raman V, Steck AK, Toledo FGS, Wentworth J, Wherrett D, White P, You L, Herold KC, Type 1 Diabetes TrialNet Study Group. PMID: 37708415; PMCID: PMC10620539.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med. 2023 Dec 07; 389(23):2151-2161. Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC, PROTECT Study Investigators. PMID: 37861217.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    8. Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review. Commun Med (Lond). 2023 Oct 05; 3(1):130. Felton JL, Griffin KJ, Oram RA, Speake C, Long SA, Onengut-Gumuscu S, Rich SS, Monaco GSF, Evans-Molina C, DiMeglio LA, Ismail HM, Steck AK, Dabelea D, Johnson RK, Urazbayeva M, Gitelman S, Wentworth JM, Redondo MJ, Sims EK, ADA/EASD PMDI. PMID: 37794169; PMCID: PMC10550983.
      View in: PubMed   Mentions: 4  
    9. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023 Oct; 29(10):2438-2457. Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, Clark AL, Colclough K, Corcoy R, Cromer SJ, Duan D, Felton JL, Francis EC, Gillard P, Gingras V, Gaillard R, Haider E, Hughes A, Ikle JM, Jacobsen LM, Kahkoska AR, Kettunen JLT, Kreienkamp RJ, Lim LL, Männistö JME, Massey R, Mclennan NM, Miller RG, Morieri ML, Most J, Naylor RN, Ozkan B, Patel KA, Pilla SJ, Prystupa K, Raghavan S, Rooney MR, Schön M, Semnani-Azad Z, Sevilla-Gonzalez M, Svalastoga P, Takele WW, Tam CH, Thuesen ACB, Tosur M, Wallace AS, Wang CC, Wong JJ, Yamamoto JM, Young K, Amouyal C, Andersen MK, Bonham MP, Chen M, Cheng F, Chikowore T, Chivers SC, Clemmensen C, Dabelea D, Dawed AY, Deutsch AJ, Dickens LT, DiMeglio LA, Dudenhöffer-Pfeifer M, Evans-Molina C, Fernández-Balsells MM, Fitipaldi H, Fitzpatrick SL, Gitelman SE, Goodarzi MO, Grieger JA, Guasch-Ferré M, Habibi N, Hansen T, Huang C, Harris-Kawano A, Ismail HM, Hoag B, Johnson RK, Jones AG, Koivula RW, Leong A, Leung GKW, Libman IM, Liu K, Long SA, Lowe WL, Morton RW, Motala AA, Onengut-Gumuscu S, Pankow JS, Pathirana M, Pazmino S, Perez D, Petrie JR, Powe CE, Quinteros A, Jain R, Ray D, Ried-Larsen M, Saeed Z, Santhakumar V, Kanbour S, Sarkar S, Monaco GSF, Scholtens DM, Selvin E, Sheu WH, Speake C, Stanislawski MA, Steenackers N, Steck AK, Stefan N, Støy J, Taylor R, Tye SC, Ukke GG, Urazbayeva M, Van der Schueren B, Vatier C, Wentworth JM, Hannah W, White SL, Yu G, Zhang Y, Zhou SJ, Beltrand J, Polak M, Aukrust I, de Franco E, Flanagan SE, Maloney KA, McGovern A, Molnes J, Nakabuye M, Njølstad PR, Pomares-Millan H, Provenzano M, Saint-Martin C, Zhang C, Zhu Y, Auh S, de Souza R, Fawcett AJ, Gruber C, Mekonnen EG, Mixter E, Sherifali D, Eckel RH, Nolan JJ, Philipson LH, Brown RJ, Billings LK, Boyle K, Costacou T, Dennis JM, Florez JC, Gloyn AL, Gomez MF, Gottlieb PA, Greeley SAW, Griffin K, Hattersley AT, Hirsch IB, Hivert MF, Hood KK, Josefson JL, Kwak SH, Laffel LM, Lim SS, Loos RJF, Ma RCW, Mathieu C, Mathioudakis N, Meigs JB, Misra S, Mohan V, Murphy R, Oram R, Owen KR, Ozanne SE, Pearson ER, Perng W, Pollin TI, Pop-Busui R, Pratley RE, Redman LM, Redondo MJ, Reynolds RM, Semple RK, Sherr JL, Sims EK, Sweeting A, Tuomi T, Udler MS, Vesco KK, Vilsbøll T, Wagner R, Rich SS, Franks PW. PMID: 37794253; PMCID: PMC10735053.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    10. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes Care. 2023 10 01; 46(10):1848-1856. Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. PMID: 37607392; PMCID: PMC10545553.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    11. β-Cell Glucose Sensitivity to Assess Changes in β-Cell Function in Recent-Onset Stage 3 Type 1 Diabetes. Diabetes. 2023 09 01; 72(9):1289-1296. Gitelman SE, Evans-Molina C, Guolo A, Mari A, Ferrannini E. PMID: 37368990; PMCID: PMC10450822.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    12. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care. 2023 05 01; 46(5):1005-1013. Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC, Type 1 Diabetes TrialNet Study Group. PMID: 36920087; PMCID: PMC10154649.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    13. Type 1 Diabetes Prevention: a systematic review of studies testing disease-modifying therapies and features linked to treatment response. medRxiv. 2023 Apr 17. Felton JL, Griffin KJ, Oram RA, Speake C, Long SA, Onengut-Gumuscu S, Rich SS, Monaco GS, Evans-Molina C, DiMeglio LA, Ismail HM, Steck AK, Dabelea D, Johnson RK, Urazbayeva M, Gitelman S, Wentworth JM, Redondo MJ, Sims EK. PMID: 37131690; PMCID: PMC10153317.
      View in: PubMed   Mentions:
    14. Real-Time Continuous Glucose Monitoring in Adolescents and Young Adults With Type 2 Diabetes Can Improve Quality of Life. J Diabetes Sci Technol. 2024 Jul; 18(4):911-919. Chesser H, Srinivasan S, Puckett C, Gitelman SE, Wong JC. PMID: 36416098; PMCID: PMC11307231.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    15. The Transition From a Compensatory Increase to a Decrease in C-peptide During the Progression to Type 1 Diabetes and Its Relation to Risk. Diabetes Care. 2022 10 01; 45(10):2264-2270. Ismail HM, Cuthbertson D, Gitelman SE, Skyler JS, Steck AK, Rodriguez H, Atkinson M, Nathan BM, Redondo MJ, Herold KC, Evans-Molina C, DiMeglio LA, Sosenko J, DPT-1 and TrialNet Study Groups. PMID: 35998266; PMCID: PMC9643141.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Preferences for Risks and Benefits of Islet Cell Transplantation for Persons With Type 1 Diabetes With History of Episodes of Severe Hypoglycemia: A Discrete-Choice Experiment to Inform Regulatory Decisions. Transplantation. 2022 08 01; 106(8):e368-e379. Wilson L, Kwok T, Ma Y, Wong J, Ho M, Ionova Y, McGrath M, Mueller MM, Gitelman SE, Irony T. PMID: 35655355.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight. 2021 11 08; 6(21). Greenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S, ITN058AI EXTEND Study Team. PMID: 34747368; PMCID: PMC8663550.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    18. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight. 2021 09 22; 6(18). Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA. PMID: 34324441; PMCID: PMC8492314.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCellsCTClinical Trials
    19. Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia. 2021 11; 64(11):2432-2444. Bediaga NG, Li-Wai-Suen CSN, Haller MJ, Gitelman SE, Evans-Molina C, Gottlieb PA, Hippich M, Ziegler AG, Lernmark A, DiMeglio LA, Wherrett DK, Colman PG, Harrison LC, Wentworth JM. PMID: 34338806; PMCID: PMC8494707.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    20. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021 08; 9(8):502-514. Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Gleevec Trial Study Group. PMID: 34214479; PMCID: PMC8494464.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    21. Youth with Type 1 Diabetes Had Improvement in Continuous Glucose Monitoring Metrics During the COVID-19 Pandemic. Diabetes Technol Ther. 2021 10; 23(10):684-691. Abdulhussein FS, Chesser H, Boscardin WJ, Gitelman SE, Wong JC. PMID: 34042523; PMCID: PMC8573792.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    22. Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. Diabetes. 2021 05; 70(5):1123-1129. Lin A, Mack JA, Bruggeman B, Jacobsen LM, Posgai AL, Wasserfall CH, Brusko TM, Atkinson MA, Gitelman SE, Gottlieb PA, Gurka MJ, Mathews CE, Schatz DA, Haller MJ. PMID: 33632742; PMCID: PMC8173803.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    23. Continuous Glucose Monitoring to Diagnose Hypoglycemia Due to Late Dumping Syndrome in Children After Gastric Surgeries. J Endocr Soc. 2021 Mar 01; 5(3):bvaa197. Chesser H, Abdulhussein F, Huang A, Lee JY, Gitelman SE. PMID: 33506160; PMCID: PMC7814385.
      View in: PubMed   Mentions: 3  
    24. Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technol Ther. 2020 12; 22(12):948-953. Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, Mathews CE, Herold KC, Gitelman SE, Krischer JP, Haller MJ. PMID: 32833543; PMCID: PMC7757538.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    25. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obes Metab. 2020 11; 22(11):2045-2054. Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop-Busui R, Weinstock RS. PMID: 32573927; PMCID: PMC8009602.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    26. Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia. 2020 04; 63(4):885-886. Wentworth JM, Bediaga NG, Gitelman SE, Evans-Molina C, Gottlieb PA, Colman PG, Haller MJ, Harrison LC. PMID: 31982961; PMCID: PMC8159479.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents. Diabetes Care. 2020 03; 43(3):580-587. Ferrara-Cook C, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group. PMID: 31937610; PMCID: PMC7035590.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    28. Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes. JCI Insight. 2019 12 19; 4(24). Herold KC, Bucktrout SL, Wang X, Bode BW, Gitelman SE, Gottlieb PA, Hughes J, Joh T, McGill JB, Pettus JH, Potluri S, Schatz D, Shannon M, Udata C, Wong G, Levisetti M, Ganguly BJ, Garzone PD, RN168 Working Group. PMID: 31852846; PMCID: PMC6975260.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    29. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care. 2020 01; 43(1):5-12. Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M. PMID: 31753960; PMCID: PMC6925574.
      View in: PubMed   Mentions: 147     Fields:    Translation:Humans
    30. Elicited and pre-existing anti-Neu5Gc antibodies differentially affect human endothelial cells transcriptome. Xenotransplantation. 2019 11; 26(6):e12535. Le Berre L, Danger R, Mai HL, Amon R, Leviatan Ben-Arye S, Bruneau S, Senage T, Perreault H, Teraiya M, Nguyen TVH, Le Tourneau T, Yu H, Chen X, Galli C, Roussel JC, Manez R, Costa C, Brouard S, Galinanes M, Harris KM, Gitelman S, Cozzi E, Charreau B, Padler-Karavani V, Soulillou JP. PMID: 31293002.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    31. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 08 15; 381(7):603-613. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. PMID: 31180194; PMCID: PMC6776880.
      View in: PubMed   Mentions: 374     Fields:    Translation:HumansCellsCTClinical Trials
    32. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes. 2019 06; 68(6):1267-1276. Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ, Type 1 Diabetes TrialNet ATG-GCSF Study Group. PMID: 30967424; PMCID: PMC6610026.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCellsCTClinical Trials
    33. Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables. Diabetologia. 2019 01; 62(1):33-40. Wentworth JM, Bediaga NG, Giles LC, Ehlers M, Gitelman SE, Geyer S, Evans-Molina C, Harrison LC, Type 1 Diabetes TrialNet Study Group, Immune Tolerance Network Study Group. PMID: 30167735; PMCID: PMC6518395.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    34. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care. 2018 Sep; 41(9):1917-1925. Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ, Type 1 Diabetes TrialNet ATG-GCSF Study Group. PMID: 30012675; PMCID: PMC6105329.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    35. Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy. Oncotarget. 2017 Dec 22; 8(68):112236-112244. Amon R, Ben-Arye SL, Engler L, Yu H, Lim N, Berre LL, Harris KM, Ehlers MR, Gitelman SE, Chen X, Soulillou JP, Padler-Karavani V. PMID: 29348821; PMCID: PMC5762506.
      View in: PubMed   Mentions: 23     Fields:    
    36. The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults. J Clin Endocrinol Metab. 2017 12 01; 102(12):4596-4603. Ferrara CT, Geyer SM, Evans-Molina C, Libman IM, Becker DJ, Wentworth JM, Moran A, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group. PMID: 29092051; PMCID: PMC5718698.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    37. A new familial form of a late-onset, persistent hyperinsulinemic hypoglycemia of infancy caused by a novel mutation in KCNJ11. Channels (Austin). 2017 Nov 02; 11(6):636-647. Yang YY, Long RK, Ferrara CT, Gitelman SE, German MS, Yang SB. PMID: 29087246; PMCID: PMC5786184.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. Type 1 Diabetes and Celiac Disease: Causal Association or True, True, Unrelated? Pediatrics. 2017 11; 140(5). Ferrara CT, Gitelman SE. PMID: 29018047.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Anti-Gal and Anti-Neu5Gc Responses in Nonimmunosuppressed Patients After Treatment With Rabbit Antithymocyte Polyclonal IgGs. Transplantation. 2017 10; 101(10):2501-2507. Salama A, Evanno G, Lim N, Rousse J, Le Berre L, Nicot A, Bach JM, Brouard S, Harris KM, Ehlers MR, Gitelman SE, Soulillou JP. PMID: 28198767.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCTClinical Trials
    40. Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development? Diabetes Care. 2017 05; 40(5):698-701. Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ, Rodriguez H, Moran A, Gitelman SE, Redondo MJ, Type 1 Diabetes TrialNet Study Group. PMID: 28202550; PMCID: PMC5399656.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    41. Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. Diabetes Care. 2016 Dec; 39(12):2218-2224. Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY. PMID: 27872156; PMCID: PMC5127223.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    42. Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. Diabetes. 2016 Dec; 65(12):3765-3775. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai AL, Mathews CE, Brusko TM, Atkinson MA, Schatz DA. PMID: 27669730; PMCID: PMC5127248.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    43. Regulatory T cell therapy for type 1 diabetes: May the force be with you. J Autoimmun. 2016 07; 71:78-87. Gitelman SE, Bluestone JA. PMID: 27133597.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    44. Two- and Four-Hour Tests Differ in Capture of C-Peptide Responses to a Mixed Meal in Type 1 Diabetes. Diabetes Care. 2016 06; 39(6):e76-8. Boyle KD, Keyes-Elstein L, Ehlers MR, McNamara J, Rigby MR, Gitelman SE, Weiner LJ, Much KL, Herold KC. PMID: 27208317; PMCID: PMC4878222.
      View in: PubMed   Mentions: 2     Fields:    
    45. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial. Diabetologia. 2016 06; 59(6):1153-61. Gitelman SE, Gottlieb PA, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Harris KM, Kanaparthi S, Phippard D, Ding L, Bluestone JA, Ehlers MR, ITN START Study Team. PMID: 27053235; PMCID: PMC4869699.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    46. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med. 2015 Nov 25; 7(315):315ra189. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. PMID: 26606968; PMCID: PMC4729454.
      View in: PubMed   Mentions: 508     Fields:    Translation:HumansCellsCTClinical Trials
    47. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care. 2015 Oct; 38(10):1975-85. Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. PMID: 26404927; PMCID: PMC4876737.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    48. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 03; 125(8):3285-96. Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. PMID: 26193635; PMCID: PMC4623571.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCellsCTClinical Trials
    49. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest. 2015 Jan; 125(1):448-55. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA. PMID: 25500887; PMCID: PMC4382237.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCellsCTClinical Trials
    50. Recommendations for the definition of clinical responder in insulin preservation studies. Diabetes. 2014 Sep; 63(9):3120-7. Beam CA, Gitelman SE, Palmer JP, Type 1 Diabetes TrialNet Study Group. PMID: 24722251; PMCID: PMC4141373.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    51. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014 Apr; 37(4):1069-75. Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. PMID: 24296850; PMCID: PMC3964491.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    52. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):284-94. Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, T1DAL Study Team. PMID: 24622414; PMCID: PMC3957186.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCellsCTClinical Trials
    53. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2014 Feb; 37(2):453-9. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group. PMID: 24026563; PMCID: PMC3898764.
      View in: PubMed   Mentions: 121     Fields:    Translation:HumansCellsCTClinical Trials
    54. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):306-16. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, START Study Team. PMID: 24622416; PMCID: PMC6489466.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    55. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov; 62(11):3766-74. Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA, AbATE Study Team. PMID: 23835333; PMCID: PMC3806618.
      View in: PubMed   Mentions: 175     Fields:    Translation:Humans
    56. Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr Diabetes. 2013 Aug; 14(5):311-21. Thomas HR, Gitelman SE. PMID: 23773203; PMCID: PMC3748836.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    57. Combined pancreatic islet and kidney transplantation in a child with unstable type 1 diabetes and end-stage renal disease. Am J Transplant. 2013 Aug; 13(8):2207-10. Benedict KA, Moassesfar S, Adi S, Gitelman SE, Brennan JL, McEnhill M, Stock PG, Portale AA, Posselt AM. PMID: 23763601; PMCID: PMC4063279.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    58. Comparison of autoantibody-positive and autoantibody-negative pediatric participants enrolled in the T1D Exchange clinic registry. J Diabetes. 2013 Jun; 5(2):216-23. Gerard-Gonzalez A, Gitelman SE, Cheng P, Dubose SN, Miller KM, Olson BA, Redondo MJ, Steck AK, Beck RW. PMID: 23368514; PMCID: PMC6779047.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    59. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet. 2013 Jun 01; 381(9881):1905-15. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab Study Group, Pickersgill L, de Koning E, Ziegler AG, Böehm B, Badenhoop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castaño L, Wägner A, Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group. PMID: 23562090; PMCID: PMC3827771.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansCells
    60. A cross-sectional study of osteocalcin and body fat measures among obese adolescents. Obesity (Silver Spring). 2013 Apr; 21(4):808-14. Lenders CM, Lee PD, Feldman HA, Wilson DM, Abrams SH, Gitelman SE, Klish WJ, Wertz MS, Taylor GA, Alongi RT, Chen TC, Holick MF, Elisabeth Glaser Pediatric Research Network Obesity Study Group. PMID: 23712984; PMCID: PMC4854645.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    61. Immune therapy and β-cell death in type 1 diabetes. Diabetes. 2013 May; 62(5):1676-80. Lebastchi J, Deng S, Lebastchi AH, Beshar I, Gitelman S, Willi S, Gottlieb P, Akirav EM, Bluestone JA, Herold KC. PMID: 23423576; PMCID: PMC3636605.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    62. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia. 2013 Feb; 56(2):391-400. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. PMID: 23086558; PMCID: PMC3537871.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    63. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012 Aug; 61(8):2066-73. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group. PMID: 22688329; PMCID: PMC3402330.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCells
    64. Persistent elevation of urine aquaporin-2 during water loading in a child with nephrogenic syndrome of inappropriate antidiuresis (NSIAD) caused by a R137L mutation in the V2 vasopressin receptor. Int J Pediatr Endocrinol. 2012 Feb 10; 2012(1):3. Cheung CC, Cadnapaphornchai MA, Ranadive SA, Gitelman SE, Rosenthal SM. PMID: 22325688; PMCID: PMC3299583.
      View in: PubMed   Mentions: 4  
    65. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Jul 30; 378(9789):412-9. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Abatacept Study Group. PMID: 21719096; PMCID: PMC3462593.
      View in: PubMed   Mentions: 289     Fields:    Translation:HumansCellsCTClinical Trials
    66. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 2011 Jul 23; 378(9788):319-27. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet GAD Study Group. PMID: 21714999; PMCID: PMC3580128.
      View in: PubMed   Mentions: 169     Fields:    Translation:Humans
    67. Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population? Pediatr Diabetes. 2011 Jun; 12(4 Pt 2):442-59. Glaser NS, Geller DH, Haqq A, Gitelman S, Malloy M, Lawson Wilkins Pediatric Endocrine Society Committee on Drugs and Therapeutics. PMID: 21054719.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    68. Impact of an interactive online nursing educational module on insulin errors in hospitalized pediatric patients. Diabetes Care. 2010 Aug; 33(8):1744-6. Sullivan MM, O'Brien CR, Gitelman SE, Shapiro SE, Rushakoff RJ. PMID: 20504898; PMCID: PMC2909054.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    69. Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol. 2010 May; 77(5):836-45. Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, Bouvier M. PMID: 20159941; PMCID: PMC2872969.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    70. Long-term outcomes in a family with nephrogenic syndrome of inappropriate antidiuresis. Int J Pediatr Endocrinol. 2009; 2009:431527. Cho YH, Gitelman S, Rosenthal S, Ambler G. PMID: 20148077; PMCID: PMC2817859.
      View in: PubMed   Mentions: 7  
    71. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009 Nov 26; 361(22):2143-52. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group. PMID: 19940299; PMCID: PMC6410357.
      View in: PubMed   Mentions: 474     Fields:    Translation:HumansCells
    72. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2009 Aug 12; 302(6):624; author reply 624-5. Gitelman SE, Haller MJ, Schatz D. PMID: 19671901.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    73. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. Am J Clin Nutr. 2009 Sep; 90(3):459-67. Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, Wilson DM, Lee PD, Abrams SH, Gitelman SE, Wertz MS, Klish WJ, Taylor GA, Chen TC, Holick MF, Elizabeth Glaser Pediatric Research Network Obesity Study Group. PMID: 19640956; PMCID: PMC2728638.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    74. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol. 2009 Aug; 132(2):166-73. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA, Immune Tolerance Network ITN007AI Study Group. PMID: 19443276; PMCID: PMC2735402.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    75. The effect of oral alpha-lipoic acid on oxidative stress in adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2008 Jun; 9(3 Pt 2):69-73. Huang EA, Gitelman SE. PMID: 18221433.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    76. Congenital hyperinsulinism in an infant caused by a macroscopic insulin-producing lesion. J Pediatr Endocrinol Metab. 2007 Mar; 20(3):437-40. Bremer AA, Nobuhara KK, Gitelman SE. PMID: 17451083.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    77. Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction. Pediatr Endocrinol Rev. 2006 Dec; 4 Suppl 1:66-70. Rosenthal SM, Feldman BJ, Vargas GA, Gitelman SE. PMID: 17261972.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    78. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006 Sep; 55(9):2588-94. Seyfert-Margolis V, Gisler TD, Asare AL, Wang RS, Dosch HM, Brooks-Worrell B, Eisenbarth GS, Palmer JP, Greenbaum CJ, Gitelman SE, Nepom GT, Bluestone JA, Herold KC. PMID: 16936208.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    79. Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients. Am J Med. 2006 Jul; 119(7 Suppl 1):S54-8. Gitelman SE, Feldman BJ, Rosenthal SM. PMID: 16843086.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    80. Oral urea for the treatment of chronic syndrome of inappropriate antidiuresis in children. J Pediatr. 2006 Jan; 148(1):128-31. Huang EA, Feldman BJ, Schwartz ID, Geller DH, Rosenthal SM, Gitelman SE. PMID: 16423613.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    81. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab. 2005 Sep; 18(9):865-72. Sapru A, Gitelman SE, Bhatia S, Dubin RF, Newman TB, Flori H. PMID: 16279364.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    82. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005 Jun; 54(6):1763-9. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. PMID: 15919798; PMCID: PMC5315015.
      View in: PubMed   Mentions: 237     Fields:    Translation:HumansCTClinical Trials
    83. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005 May 05; 352(18):1884-90. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE. PMID: 15872203; PMCID: PMC5340184.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCells
    84. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005 Jan; 28(1):15-9. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. PMID: 15616227.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    85. The use of a continuous glucose monitoring system in hypoglycemic disorders. J Pediatr Endocrinol Metab. 2004 Mar; 17(3):281-8. Conrad SC, Mastrototaro JJ, Gitelman SE. PMID: 15112904.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    86. Insulin secretion in type 1 diabetes. Diabetes. 2004 Feb; 53(2):426-33. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. PMID: 14747294.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCTClinical Trials
    87. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002 May 30; 346(22):1692-8. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. PMID: 12037148.
      View in: PubMed   Mentions: 439     Fields:    Translation:HumansCTClinical Trials
    88. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr. 2002 Feb; 140(2):235-40. Conrad SC, McGrath MT, Gitelman SE. PMID: 11865277.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    89. Increased incidence in post-transplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol. 2002 Jan; 17(1):1-5. Greenspan LC, Gitelman SE, Leung MA, Glidden DV, Mathias RS. PMID: 11793126.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    90. Peptide mapping and characterisation of glycation patterns of the glima 38 antigen recognised by autoantibodies in Type I diabetic patients. Diabetologia. 2000 May; 43(5):598-608. Roll U, Turck CW, Gitelman SE, Rosenthal SM, Nolte MS, Masharani U, Ziegler AG, Baekkeskov S. PMID: 10855535.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    91. Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development. 1999 Oct; 126(19):4267-79. Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R. PMID: 10477295.
      View in: PubMed   Mentions: 79     Fields:    Translation:AnimalsCells
    92. Smooth muscle expresses bone morphogenetic protein (Vgr-1/BMP-6) in human fetal intestine. Biol Neonate. 1999 Mar; 75(3):210-4. Perr HA, Ye J, Gitelman SE. PMID: 9925908.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    93. Neonatal hyperinsulinism. Clin Perinatol. 1998 Dec; 25(4):1015-38, viii. Schwitzgebel VM, Gitelman SE. PMID: 9891627.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    94. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab. 1997 Oct; 82(10):3196-202. Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, Wilson CB, Gitelman SE. PMID: 9329338.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimals
    95. Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents. J Clin Endocrinol Metab. 1997 May; 82(5):1362-7. Mootha SL, Barkovich AJ, Grumbach MM, Edwards MS, Gitelman SE, Kaplan SL, Conte FA. PMID: 9141516.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    96. Structure and sequence of the mouse Bmp6 gene. Mamm Genome. 1997 Mar; 8(3):212-4. Gitelman SE, Kobrin M, Lee A, Fet V, Lyons K, Hogan BL, Derynck R. PMID: 9069123.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    97. Immunoreactive inhibin, müllerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors. J Pediatr. 1996 Dec; 129(6):918-21. Silverman LA, Gitelman SE. PMID: 8969738.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    98. A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element? Hum Mol Genet. 1995 Nov; 4(11):2109-16. Tee MK, Babalola GO, Aza-Blanc P, Speek M, Gitelman SE, Miller WL. PMID: 8589688.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    99. Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells. Cell Growth Differ. 1995 Jul; 6(7):827-36. Gitelman SE, Kirk M, Ye JQ, Filvaroff EH, Kahn AJ, Derynck R. PMID: 7547504.
      View in: PubMed   Mentions: 10     Fields:    Translation:Cells
    100. Toward a molecular understanding of skeletal development. Cell. 1995 Feb 10; 80(3):371-8. Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R. PMID: 7859279.
      View in: PubMed   Mentions: 134     Fields:    Translation:HumansAnimals
    101. Recombinant Vgr-1/BMP-6-expressing tumors induce fibrosis and endochondral bone formation in vivo. J Cell Biol. 1994 Sep; 126(6):1595-609. Gitelman SE, Kobrin MS, Ye JQ, Lopez AR, Lee A, Derynck R. PMID: 8089189; PMCID: PMC2290953.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    102. Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol. 1993 Jul; 122(1):265-78. Bristow J, Tee MK, Gitelman SE, Mellon SH, Miller WL. PMID: 7686164; PMCID: PMC2119596.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCells
    103. Abundant adrenal-specific transcription of the human P450c21A "pseudogene". J Biol Chem. 1993 Jun 15; 268(17):12919-24. Bristow J, Gitelman SE, Tee MK, Staels B, Miller WL. PMID: 7685353.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    104. Mental retardation locus in Xp21 chromosome microdeletion. Am J Med Genet. 1993 Jun 01; 46(4):363-8. Fries MH, Lebo RV, Schonberg SA, Golabi M, Seltzer WK, Gitelman SE, Golbus MS. PMID: 8357005.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    105. Congenital lipoid adrenal hyperplasia--genes for P450scc, side chain cleavage enzyme, are normal. J Steroid Biochem Mol Biol. 1993 Apr; 45(1-3):87-97. Saenger P, Lin D, Gitelman SE, Miller WL. PMID: 8481356.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    106. Analysis of the duplicated human C4/P450c21/X gene cluster. J Steroid Biochem Mol Biol. 1992 Dec; 43(8):961-71. Miller WL, Gitelman SE, Bristow J, Morel Y. PMID: 22217841.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    107. Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus. Mol Cell Biol. 1992 Jul; 12(7):3313-4. Gitelman SE, Bristow J, Miller WL. PMID: 1620134; PMCID: PMC364546.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    108. Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus. Mol Cell Biol. 1992 May; 12(5):2124-34. Gitelman SE, Bristow J, Miller WL. PMID: 1373808; PMCID: PMC364384.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    109. Normal genes for the cholesterol side chain cleavage enzyme, P450scc, in congenital lipoid adrenal hyperplasia. J Clin Invest. 1991 Dec; 88(6):1955-62. Lin D, Gitelman SE, Saenger P, Miller WL. PMID: 1661294; PMCID: PMC295776.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    110. Cloning of the LH/CG receptor: implications for a unique G-protein coupled receptor. Trends Endocrinol Metab. 1990 Mar-Apr; 1(4):181-4. Gitelman SE. PMID: 18411115.
      View in: PubMed   Mentions:    Fields:    
    111. Transcript encoded on the opposite strand of the human steroid 21-hydroxylase/complement component C4 gene locus. Proc Natl Acad Sci U S A. 1989 Sep; 86(17):6582-6. Morel Y, Bristow J, Gitelman SE, Miller WL. PMID: 2475872; PMCID: PMC297888.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    112. Purification of calmodulin from Chlamydomonas: calmodulin occurs in cell bodies and flagella. J Cell Biol. 1980 Dec; 87(3 Pt 1):764-70. Gitelman SE, Witman GB. PMID: 6257728; PMCID: PMC2110766.
      View in: PubMed   Mentions: 31     Fields:    Translation:AnimalsCells
    Stephen's Networks
    Concepts (452)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (57)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.